Festinavir da Bristol-Myers Squibb

Da Gex Lun 20 Dic - 17:26

La Bristol-Myers Squibb acquista i diritti per commercializzare il Festinavir (nuovo NRTI).
Il farmaco ha i seguenti vantaggi:
Piu efficace e piu tollerato.

[Devi essere iscritto e connesso per vedere questo link]

Monday, December 20, 2010
Bristol-Myers Squibb To Buy Rights To Potential HIV Treatment Drug For $286 Million

New York-based Bristol-Myers Squibb (NYSE: BMY), said today that it has agreed to buy the rights to a potential HIV treatment drug, Festinavir, for $286 million from privately-held Japanese biotech firm Oncolys BioPharma.

Under the agreement, Oncolys may receive up to $286 million including upfront, development, regulatory and sales milestone payments. Oncolys will also receive royalties on the worldwide product sales.

Festinavir, currently going through Phase II testing, can be taken orally. The companies said early preclinical studies suggest that Festinavir could have an improved safety profile over previous generations of drugs. The drug was originally licensed to Oncolys by Yale University.

Bristol Myers shares are up by about 2 cents to trade at $26.51 as of 11:02 am EST.

Register here to be notified of future Bristol Myers Squibb articles.
Other Bristol Myers Squibb news

03/11/10
Bristol-Myers signs over anti-cancer compound rights in China to Simcere Pharmaceutical
More news ►

Investors interested in Bristol Myers Squibb recently viewed

African Medical Investments (AIM: AMEI)
Deltex Medical Group plc (AIM: DEMG)
NanoViricides (OTCBB: NNVC)
Pulse Health Limited (ASX: .PHG)
Regenicin (OTCBB: RGIN)